940.0000 13.50 (1.46%)
NSE Jan 14, 2026 15:31 PM
Volume: 346.8K
 

940.00
1.46%
Sharekhan
Q2FY25 revenues totaling Rs. 1,201 crore, demonstrating a significant y-o-y growth rate of 20%.EBITDA stood at Rs. 236 crore, marking a remarkable y-o-y increase of 31%.
Strides Pharma Science Ltd. is trading above all available SMAs
More from Strides Pharma Science Ltd.
Recommended